DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2027

Conditions
Liver Cancer
Interventions
PROCEDURE

DEB-TACE

"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."

Trial Locations (1)

Unknown

RECRUITING

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

Boston Scientific Corporation

INDUSTRY

lead

RenJi Hospital

OTHER